3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
5
Phase 3
5
Phase NA
2
Phase 2/3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Breast Neoplasms
2
Vomiting
1
Uterine Cervical Neoplasms
1
Trigger Finger Disorder
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pain
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Nausea
1
Mucositis
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Mast-Cell
1
Leukemia, Hairy Cell
1
Interventions
Morphine
6
Analgesia
6
nabiximols
3
Pregabalin
3
Oxycodone
3
Fentanyl
3
ziconotide
2
Surveys and Questionnaires
2
Saline Solution
2
Radiofrequency Ablation
2
Methadone
2
Lidocaine
2
Ketamine
2
Ibandronic Acid
2
Gemcitabine
2
Duloxetine Hydrochloride
2
Docetaxel
2
Botulinum Toxins, Type A
2
trimebutine 3-thiocarbamoylbenzenesulfonate
1
tanezumab
1
tandutinib
1
siltuximab
1
resiniferatoxin
1
incobotulinumtoxinA
1
imisopasem manganese
1
fulranumab
1
erenumab
1
cyclobenzaprine
1
caffeine, sodium benzoate drug combination
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pain
×
Acetaminophen
×
Clear all
NCT00712712
2025-08-29
MEDOR
Institut Bergonié
Phase 2
Completed
78 enrolled
28 charts